FDA grants Breakthrough Therapy Designation and Orphan Drug Designation to PellePharm for topical patidegib in Gorlin syndrome. PellePharm, a clinical-stage biopharmaceutical company targeting rare genetic dermatological conditions at the source, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy Designation and Orphan Drug Designation to topical patidegib for reduction of the life-long…